Youcare Pharmaceutical (SHA: 688658) announced that its YKYY018 inhalation solution recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for clinical trials aimed at the treatment and prevention of human parainfluenza virus (HPIV) infection. The asset is a globally original membrane fusion inhibitor, independently developed by the company using its full‑process AI platform.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. FDA |
| Action | IND clearance for clinical trials |
| Product | YKYY018 inhalation solution |
| Indication | Treatment and prevention of human parainfluenza virus (HPIV) infection |
| Announcement Date | 13 Nov 2026 |
| Development Platform | Independently developed via Youcare’s full‑process AI platform |
Drug Profile & Mechanism of Action
- Molecule: YKYY018, a globally original membrane fusion inhibitor – a first‑of‑its‑kind modality that blocks viral entry by inhibiting fusion of the viral envelope with the host cell membrane.
- Delivery: Formulated as an inhalation solution, targeting the respiratory tract – the primary site of HPIV, RSV, and hMPV infection – via direct local administration.
- AI‑Driven Discovery: Independently developed using Youcare Pharmaceutical’s full‑process AI platform, spanning target identification through candidate optimization.
- Pan‑Respiratory Potential: The fusion‑inhibitor mechanism is being pursued across multiple respiratory viruses, positioning YKYY018 as a broad respiratory antiviral candidate rather than a single‑pathogen asset.
Regulatory Track Record – IND History
| Date | Agency | Indication | Milestone |
|---|---|---|---|
| Nov 2025 | U.S. FDA | RSV infection – prevention and treatment | Clinical trial approval |
| Dec 2025 | NMPA (China) | RSV infection – prevention and treatment | Clinical trial approval |
| Mar–Apr 2026 | U.S. FDA & NMPA | hMPV infection – prevention and treatment | Clinical trial approvals (U.S. and China) |
| Nov 2026 | U.S. FDA | HPIV infection – treatment and prevention | IND clearance (latest) |
The HPIV clearance marks the fourth viral indication advanced for YKYY018 and the company’s third FDA IND for the molecule, reflecting consistent U.S.–China dual‑track regulatory execution.
Clinical Development Status
- Most Advanced Program: The Phase II clinical trial of YKYY018 inhalation solution for RSV infection is progressing steadily.
- HPIV Program: Clinical trial plans for the newly cleared HPIV indication, including timing, design, and enrollment, were not disclosed.
- hMPV Program: Trial status following the March–April 2026 approvals was not disclosed.
Market Impact & Outlook
- HPIV Unmet Need: Human parainfluenza virus is a leading cause of croup and lower respiratory tract illness in children and a significant threat to immunocompromised patients, yet no approved vaccine or specific antiviral exists – leaving treatment largely supportive.
- Platform Validation: Repeated IND clearances across RSV, hMPV, and now HPIV validate both the fusion‑inhibitor modality and Youcare’s AI‑driven discovery engine as a repeatable source of clinically viable candidates.
- Respiratory Franchise Buildout: A single inhaled asset spanning multiple respiratory viruses offers portfolio economics unusual in antivirals, with each indication adding potential commercial surface from one development backbone.
- Global Positioning: Dual FDA–NMPA engagement keeps both the U.S. and China markets open for YKYY018 across all four indications.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of YKYY018 inhalation solution, including ongoing and planned trials for RSV, hMPV, and HPIV infection, regulatory outcomes, and commercial potential. Actual results may differ materially due to risks including clinical efficacy and safety outcomes, trial execution and timelines, subsequent regulatory decisions in the U.S. and China, and competitive developments in respiratory antivirals.-Fineline Info & Tech
